TWI906214B - 脂質體調配物及其使用及製備方法 - Google Patents
脂質體調配物及其使用及製備方法Info
- Publication number
- TWI906214B TWI906214B TW109110461A TW109110461A TWI906214B TW I906214 B TWI906214 B TW I906214B TW 109110461 A TW109110461 A TW 109110461A TW 109110461 A TW109110461 A TW 109110461A TW I906214 B TWI906214 B TW I906214B
- Authority
- TW
- Taiwan
- Prior art keywords
- salt
- mol
- composition
- moles
- peg
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962826874P | 2019-03-29 | 2019-03-29 | |
| US62/826,874 | 2019-03-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202102231A TW202102231A (zh) | 2021-01-16 |
| TWI906214B true TWI906214B (zh) | 2025-12-01 |
Family
ID=72666933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109110461A TWI906214B (zh) | 2019-03-29 | 2020-03-27 | 脂質體調配物及其使用及製備方法 |
Country Status (19)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021011876A (es) | 2019-03-29 | 2022-01-04 | Glycomine Inc | Formulaciones liposomicas y metodos de uso y preparacion de las mismas. |
| US20250248939A1 (en) * | 2022-04-18 | 2025-08-07 | City Of Hope | Lipid nanoparticles, nucleic acids, and methods of use |
| TW202543582A (zh) * | 2024-02-29 | 2025-11-16 | 美商葛里柯麥公司 | 脂質體調配物及其使用及製備方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110014272A1 (en) * | 2009-05-14 | 2011-01-20 | Sanofi Pasteur | Method for adjuvanting lipopolysaccharide (LPS) of Gram-negative bacteria |
| US20160228364A1 (en) * | 2013-09-16 | 2016-08-11 | Glycomine, Inc. | Pharmaceutical preparation of carbohydrates for therapeutic use |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5997899A (en) | 1996-10-01 | 1999-12-07 | Skyepharma Inc. | Method for producing liposomes with increased percent of compound encapsulated |
| WO2000051565A1 (en) | 1999-03-02 | 2000-09-08 | The Liposome Company, Inc. | Encapsulation of bioactive complexes in liposomes |
| US7060291B1 (en) * | 1999-11-24 | 2006-06-13 | Transave, Inc. | Modular targeted liposomal delivery system |
| US7189705B2 (en) | 2000-04-20 | 2007-03-13 | The University Of British Columbia | Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers |
| US7011845B2 (en) | 2000-05-09 | 2006-03-14 | Mcp Hahnemann University | β-glucans encapsulated in liposomes |
| HUP0303616A3 (en) | 2001-03-26 | 2006-07-28 | Alza Corp Mountain View | Liposome composition for improved intracellular delivery of a therapeutic agent |
| CA2471960A1 (en) | 2002-01-09 | 2003-07-24 | Elan Pharmaceuticals, Inc. | Efficient liposomal encapsulation |
| EP1478341A4 (en) | 2002-01-09 | 2009-05-20 | Transave Inc | EFFICIENT ENCAPSULATION OF NUCLEIC ACIDS IN MEDIUM SIZE LIPOSOMES |
| WO2004103510A2 (en) | 2003-05-14 | 2004-12-02 | The Regents Of The University Of Colorado | Methods and apparatus using electrostatic atomization to form liquid vesicles |
| EP1643971A2 (en) | 2003-05-22 | 2006-04-12 | Neopharm, Inc. | Liposomal formulations comprising a combination of two or more active agents |
| JP2008518925A (ja) | 2004-10-29 | 2008-06-05 | ネオファーム、インコーポレイティッド | リポソーム製剤の製造プロセス |
| FR2897779B1 (fr) | 2006-02-24 | 2009-04-17 | Orphan Europ Sarl | Manossyl-1 phosphates, procede de preparation et utilisation en therapeutique, notamment vis-a-vis dy syndrome cdg-la |
| KR20100127842A (ko) | 2008-03-26 | 2010-12-06 | 유니버시티 오브 옥스퍼드 | 소포체 표적화 리포좀 |
| WO2010138550A1 (en) | 2009-05-27 | 2010-12-02 | Northeastern University | Conjugated nanodelivery vehicles |
| WO2011076807A2 (en) | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| US20110257233A1 (en) | 2010-03-19 | 2011-10-20 | Sanford-Burnham Medical Research Institute | Benzoisothiazolones as inhibitors of phosphomannose isomerase |
| EP2598120B1 (en) | 2010-07-31 | 2018-09-05 | The Scripps Research Institute | Compositions and methods for inducing immune tolerance |
| PT2750707T (pt) | 2011-08-31 | 2019-01-23 | Glaxosmithkline Biologicals Sa | Lipossomas peguilados para distribuição de arn que codifica imunogénio |
| HK1206644A1 (en) | 2012-03-29 | 2016-01-15 | Shire Human Genetic Therapies, Inc. | Lipid-derived neutral nanoparticles |
| WO2014063757A1 (en) | 2012-10-26 | 2014-05-01 | Universiteit Leiden | Delivery methods |
| CN104884637A (zh) | 2012-11-05 | 2015-09-02 | 普隆奈治疗公司 | 利用生物标志物通过bcl2表达的调节治疗癌症的方法 |
| US20150132369A1 (en) | 2013-11-09 | 2015-05-14 | Exir Nano Sina Company | Nanoliposomal cyclosorin formulations for immunosuppresion and methods for the production thereof |
| CN107207614B (zh) | 2014-10-09 | 2022-01-11 | 利普泰克有限公司 | 嵌合蛋白 |
| US20170165374A1 (en) | 2015-11-18 | 2017-06-15 | Insmed, Inc. | Compositions and methods for treating bacterial infections |
| MX2021011876A (es) | 2019-03-29 | 2022-01-04 | Glycomine Inc | Formulaciones liposomicas y metodos de uso y preparacion de las mismas. |
-
2020
- 2020-03-27 MX MX2021011876A patent/MX2021011876A/es unknown
- 2020-03-27 EP EP20782039.0A patent/EP3946365A4/en active Pending
- 2020-03-27 US US17/593,755 patent/US12691131B2/en active Active
- 2020-03-27 AR ARP200100841A patent/AR119705A1/es unknown
- 2020-03-27 TW TW109110461A patent/TWI906214B/zh active
- 2020-03-27 AU AU2020252005A patent/AU2020252005B2/en active Active
- 2020-03-27 BR BR112021019593A patent/BR112021019593A2/pt unknown
- 2020-03-27 SG SG11202110623PA patent/SG11202110623PA/en unknown
- 2020-03-27 PE PE2021001645A patent/PE20212366A1/es unknown
- 2020-03-27 EA EA202192663A patent/EA202192663A1/ru unknown
- 2020-03-27 WO PCT/US2020/025246 patent/WO2020205530A1/en not_active Ceased
- 2020-03-27 CN CN202080038191.4A patent/CN113873998A/zh active Pending
- 2020-03-27 PH PH1/2021/552428A patent/PH12021552428A1/en unknown
- 2020-03-27 KR KR1020217035257A patent/KR20210143906A/ko active Pending
- 2020-03-27 CA CA3134828A patent/CA3134828A1/en active Pending
- 2020-03-27 JP JP2021560323A patent/JP7583741B2/ja active Active
- 2020-03-27 IL IL286713A patent/IL286713B2/en unknown
-
2021
- 2021-09-28 CL CL2021002512A patent/CL2021002512A1/es unknown
- 2021-10-26 CO CONC2021/0014274A patent/CO2021014274A2/es unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110014272A1 (en) * | 2009-05-14 | 2011-01-20 | Sanofi Pasteur | Method for adjuvanting lipopolysaccharide (LPS) of Gram-negative bacteria |
| US20160228364A1 (en) * | 2013-09-16 | 2016-08-11 | Glycomine, Inc. | Pharmaceutical preparation of carbohydrates for therapeutic use |
Also Published As
| Publication number | Publication date |
|---|---|
| EA202192663A1 (ru) | 2022-03-01 |
| KR20210143906A (ko) | 2021-11-29 |
| JP2022527638A (ja) | 2022-06-02 |
| IL286713B2 (en) | 2025-07-01 |
| SG11202110623PA (en) | 2021-10-28 |
| AU2020252005B2 (en) | 2025-11-27 |
| US12691131B2 (en) | 2026-07-28 |
| CN113873998A (zh) | 2021-12-31 |
| PH12021552428A1 (en) | 2022-07-11 |
| EP3946365A4 (en) | 2023-04-19 |
| AR119705A1 (es) | 2022-01-05 |
| CL2021002512A1 (es) | 2023-01-06 |
| IL286713A (en) | 2021-10-31 |
| IL286713B1 (en) | 2025-03-01 |
| PE20212366A1 (es) | 2021-12-21 |
| TW202102231A (zh) | 2021-01-16 |
| JP7583741B2 (ja) | 2024-11-14 |
| EP3946365A1 (en) | 2022-02-09 |
| BR112021019593A2 (pt) | 2021-12-14 |
| US20220184107A1 (en) | 2022-06-16 |
| AU2020252005A1 (en) | 2021-11-04 |
| WO2020205530A1 (en) | 2020-10-08 |
| CA3134828A1 (en) | 2020-10-08 |
| CO2021014274A2 (es) | 2022-01-17 |
| MX2021011876A (es) | 2022-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11701432B2 (en) | Polyglutamated antifolates and uses thereof | |
| EP2323693B1 (en) | Drug carriers | |
| US20240082155A1 (en) | Pharmaceutical preparation of carbohydrates for therapeutic use | |
| JP7583741B2 (ja) | リポソーム製剤、ならびにリポソーム製剤を使用および調製する方法 | |
| CA2794540A1 (en) | Methods and compositions for weight loss | |
| JP6744046B2 (ja) | cGMPアナログの標的化されたリポソーム送達 | |
| WO2007091661A1 (ja) | 分子イメージングに適した糖鎖修飾リポソームならびにその利用および製造 | |
| EA050120B1 (ru) | Липосомальные фармацевтические композиции и способ их применения | |
| TW202600145A (zh) | 治療患有先天性醣基化障礙(cdg)的個體的先天性醣基化障礙和共濟失調的方法 | |
| WO2020061670A1 (pt) | Formulação lipossomal, composição farmacêutica, uso de uma formulação lipossomal, método para tratamento de câncer, e, processo para preparação de uma formulação lipossomal | |
| BR122024017509B1 (pt) | Composições lipossomais de antifolatos poliglutamatados dglutamil, seu uso e método de preparação |